Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JMJD6 | Q6NYC1 | 8/20 | 0.51 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1982810 | 0.84 | JMJD6 (0.48) | JMJD6NUDT1 | |
| SCHEMBL1646106 | 0.82 | JMJD6 (0.55) | JMJD6NUDT1 | |
| SCHEMBL15683164 | 0.80 | CA12 (0.45) | SIRT2CYP3A4 | |
| SCHEMBL16142064 | 0.76 | JMJD6 (0.53) | JMJD6PIK3CASYKNPC1RAB9A | |
| SCHEMBL28332640 | 0.76 | JMJD6 (0.61) | JMJD6PIK3CA | |
| SCHEMBL4770741 | 0.76 | JMJD6 (0.55) | JMJD6NPC1RAB9A | |
| SCHEMBL1993315 | 0.75 | JMJD6 (0.50) | JMJD6SIRT2PIK3CANPC1RAB9A | |
| SCHEMBL30171421 | 0.75 | JMJD6 (0.76) | JMJD6PIK3CA | |
| SCHEMBL811785 | 0.75 | JMJD6 (0.76) | JMJD6PIK3CA | |
| SCHEMBL3442381 | 0.75 | JMJD6 (0.61) | JMJD6SIRT2PIK3CANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2338887-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, PON1, CBR1 | JMJD6 836/4885NUDT1 4/4885SIRT2 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.